SCHEMBL421671

SCHEMBL421671

[CH2]CCCCCC(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472150 1.00 TRPV1 (0.40)
SCHEMBL21694380 1.00 TRPV1 (0.40)
SCHEMBL6434209 1.00 TRPV1 (0.40)
SCHEMBL6440333 1.00 TRPV1 (0.40)
SCHEMBL7862202 1.00 TRPV1 (0.40)
SCHEMBL6440275 1.00 TRPV1 (0.40)
SCHEMBL21694371 1.00 TRPV1 (0.40)
SCHEMBL423131 0.97
SCHEMBL755558 0.88
SCHEMBL27904586 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556155-B2 Methods of treating fatty liver disease GENZYME CORPORATION (US) 2017-01-31 US claimed
US-9532976-B2 Method of lowering blood glucose GENZYME CORPORATION (US) 2017-01-03 US claimed
EP-2923699-A1 METHODS OF TREATING FATTY LIVER DISEASE Genzyme Corporation (US) 2015-09-30 EP claimed
US-20150190373-A1 Method of Treating Diabetes Mellitus GENZYME CORPORATION 2015-07-09 US claimed
EP-2032134-B1 METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS GENZYME CORP (US) 2015-06-24 EP claimed
US-20150051261-A1 Methods of Treating Fatty Liver Disease GENZYME CORPORATION (US) 2015-02-19 US claimed
US-8716327-B2 Methods of treating fatty liver disease GENZYME CORPORATION (US) 2014-05-06 US claimed
US-20120022126-A1 Method Of Treating Diabetes Mellitus GENZYME CORPORATION (US) 2012-01-26 US claimed
US-8003617-B2 e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease GENZYME CORPORATION (US) 2011-08-23 US claimed
US-20090105125-A1 Methods of Treating Fatty Liver Disease GENZYME CORPORATION 2009-04-23 US claimed
EP-1811991-A2 METHODS OF TREATING DIABETES MELLITUS Genzyme Corporation (US) 2007-08-01 EP claimed
WO-2006053043-A2 METHODS OF TREATING DIABETES MELLITUS GENZYME CORPORATION (US) 2006-05-18 WO claimed
EP-0584347-B1 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS CELL THERAPEUTICS INC (US) 2003-01-15 EP claimed
CN-1040646-C Enatiomeric hydroxylated xanthine compounds CELL THERAPEUTICS INC (US) 1998-11-11 CN claimed
US-5648357-A MAINTAINING HOMEOSTASIS IN RESPONSE TO INFLAMMATORY AND PROLIFERATIVE STIMULI CELL THERAPEUTICS, INC. (US) 1997-07-15 US claimed
EP-0584347-A4 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS. CELL THERAPEUTICS INC (US) 1995-04-26 EP claimed
US-5321057-A Ammonium polyphosphate microencapsulated with aminoplastic resins MINISTERO DELL'UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1994-06-14 US claimed
CN-1085557-A The enantiomorph hydroxylated xanthine compounds CELL THERAPEUTICS INC (US) 1994-04-20 CN claimed
EP-0584347-A1 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-03-02 EP claimed
WO-1993017684-A2 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS CELL THERAPEUTICS, INC. (US) 1993-09-16 WO claimed